Insurance won’t cover Ozempic? WA court sparks discrimination debate
In a decision published
Over the past few years, weight loss medications known as GLP-1 drugs have exploded in popularity. The drugs are approved by the
As a result, people prescribed GLP-1 drugs for obesity often have to pay hundreds of dollars per month out of pocket. Those who can't often turn to compounded versions of the drugs, or go without.
Last week's ruling tees up a potential legal battle that could eventually strike down blanket bans on weight loss drug coverage in
The recent ruling stems from a lawsuit filed by
That year, Simonton's doctor prescribed her a GLP-1 drug to help treat her obesity. Specifically, she needed to lose 40 pounds before she could get knee surgery.
Then a nurse at a public hospital, Simonton got insurance through the
The healthcare authority denied her GLP-1 drug coverage, leaving her to pay for it on her own. Simonton then sued.
The authority did not respond to a request for comment.
The lawsuit I filed because as a nurse I was very upset at people not having access to this medication," Simonton said in a phone interview. She grew frustrated as she learned that colleagues and patients were refused coverage for weight loss drugs just as she was. "I fought with weight my entire life, and it's been a struggle."
The case was dismissed in trial court in 2024, so her attorneys filed an appeal. The recent appellate case ruling says that insurers cannot exclude coverage for medical treatments solely based on the fact that they address obesity.
"What this says is you cannot, when you design a health insurance plan, pick out a disability and exclude coverage for that disability," said
The ruling did not find that weight loss drug coverage bans are discriminatory — only that they could be. It also does not mandate that health insurance plans cover weight loss drugs.
For now, the ruling simply kicks the case back to trial court, where insurers will have the opportunity to argue that their weight loss drug coverage bans are not discriminatory. They can do so by proving that GLP-1 drugs are not medically necessary or clinically effective, or that their cost outweighs their benefits.
But making such a case could be an uphill battle, Spoonemore said. "That's a tough burden because the science right now for the GLP-1s is so incredibly strong."
Central to the appellate court ruling are
Back in trial court, the plaintiffs will seek class certification, allowing the suit to move forward as class action, Spoonemore said. The case could also get taken up by the state Supreme Court.
The lawyer estimated that a trial would take up to a year to play out in either case.
In the meantime, Simonton is still paying out of pocket for her weight loss medication, which costs around
"It's not just about me, it's about everybody, patients and people who need access to these kinds of medication.
© 2026 The Seattle Times. Visit www.seattletimes.com. Distributed by Tribune Content Agency, LLC.


Illinois Quick Hits: Gas tops $5 a gallon
Insurity Advances 2026 Marine Suite Roadmap to Enable Marine Cargo Insurers to Generate More Certificates and Onboard Business Faster
Advisor News
- What will Democrats in Congress do about healthcare and retirement?
- Election results cloud retirement legislation outlook, experts say
- Planning for the missing chapter
- Semi-retirement: helping clients balance flexibility with financial security
- The 6X Formula for leveraging content marketing with AI
More Advisor NewsAnnuity News
- Jackson Launches Direct-to-Consumer Annuity Offering
- Global Atlantic launches ForeIncome Flex
- Athene CEO criticizes offshore reinsurance, risk-taking by competitors
- DOL, trade groups, state AGs file briefs supporting Alcoa in PRT lawsuit
- John Hancock launches new fixed indexed annuity suite
More Annuity NewsHealth/Employee Benefits News
- What will Democrats in Congress do about healthcare and retirement?
- Forms, phone calls and portals: The hidden work that keeps American institutions functioning burdens parents most
- Health Plans Expect Double-Digit Premium Increases Again in 2027
- Best’s Special Report: Rising Costs Could Offset AI-Driven Efficiency Gains at US Health Insurers
- Free Medicare counseling provided through LTADD
More Health/Employee Benefits NewsLife Insurance News
- California’s new solvency rules: What should life insurance advisors watch?
- Navigating delayed death certificates: A guide for life insurance advisors
- Jackson Launches Direct-to-Consumer Annuity Offering
- Best’s Market Segment Report: AM Best Maintains Stable Outlook on New Zealand’s Non-Life Insurance Segment
- AM Best Affirms Credit Ratings of Fubon Insurance Vietnam Co., Ltd.
More Life Insurance News